Eli Lilly and Company
CGRP receptor antagonists
Last updated:
Abstract:
The present invention provides compounds of Formula II or a pharmaceutically acceptable salts thereof, useful as a CGRP receptor antagonist. ##STR00001##
Status:
Grant
Type:
Utility
Filling date:
8 May 2018
Issue date:
20 Jul 2021